Novartis to acquire Avidity Biosciences for about $12 billion
PositiveFinancial Markets

Novartis has announced its plans to acquire Avidity Biosciences for approximately $12 billion, a move that highlights its commitment to expanding its portfolio in the biotechnology sector. This acquisition is significant as it not only strengthens Novartis's position in the market but also enhances its capabilities in developing innovative therapies. The deal reflects a growing trend in the pharmaceutical industry where large companies are investing in smaller biotech firms to access cutting-edge technologies and treatments.
— Curated by the World Pulse Now AI Editorial System









